TL;DR:
- Evogene introduces the ChemPass AI tech-engine with the groundbreaking TargetSelector application for target-protein discovery.
- TargetSelector streamlines the identification of active molecules, reducing development time and resource usage.
- Precise identification of target proteins is crucial for advancing research in pharmaceuticals, agriculture, and environmental solutions.
- The ChemPass AI tech-engine leverages predictive machine learning algorithms and genomic data to optimize the discovery process.
- AgPlenus, Evogene’s subsidiary, will be the first to benefit from this technology for novel pesticide mechanisms.
- This advancement positions Evogene to form strategic partnerships, unlock innovation, and deliver solutions for global challenges.
Main AI News:
Evogene Ltd., a trailblazing computational biology company on a mission to revolutionize life-science product discovery and development, is making waves with its cutting-edge ChemPass AI tech-engine. The latest addition to this impressive platform comes in the form of a game-changing technology for target-protein discovery – the TargetSelector application.
In the ever-evolving landscape of biotechnology, the importance of finding suitable target proteins for new products cannot be overstated. This is precisely where TargetSelector shines, streamlining the process of identifying active molecules and drastically reducing development time and resource expenditure. Researchers now have an edge, as this breakthrough technology significantly increases the probability of success.
Proteins are the fundamental building blocks of countless biological processes and represent the primary targets for developing innovative therapeutics, ag-chemicals, ag-biologicals, and other life science solutions. Accurate identification of these vital protein targets is pivotal in advancing research and discovery across various domains, from pharmaceuticals to agriculture and environmental applications.
However, identifying the right target-protein from a vast pool of candidates within a relevant organism is no small task. The ChemPass AI tech-engine, armed with predictive machine learning algorithms and genomic data, empowers researchers with valuable insights into product requirements, such as homology, druggability, essentiality, and biological pathways. This efficient narrowing down of potential target-proteins optimizes the discovery process, delivering results like never before.
Dr. Nir Arbel, Chief Product Officer at Evogene, expressed his enthusiasm for this groundbreaking development, stating, “The ChemPass AI tech-engine has already been at the forefront of identifying small molecules. With the addition of TargetSelector, we’ve unlocked an even broader scope, finding the optimal target-protein for these molecules. Our subsidiary, AgPlenus, focused on ag chemicals, will be the first to leverage this new improvement, employing it to identify novel mechanisms of action for pesticides. This significant advancement positions Evogene to establish strategic partnerships with industry leaders, unlocking innovation, expediting product development, and delivering groundbreaking solutions that address pressing global challenges.“
Conclusion:
The introduction of Evogene’s ChemPass AI tech-engine, featuring the transformative TargetSelector application, marks a pivotal moment in the market of target-protein discovery. Researchers in pharmaceuticals, agriculture, and environmental fields can now benefit from the streamlined identification of active molecules, reducing development time and resource investment. With the ability to unlock novel mechanisms for pesticides, Evogene is poised to forge strategic partnerships and deliver groundbreaking solutions that address pressing global challenges, establishing itself as a leader in the field of computational biology and life-science product development.
